{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:31:07Z","timestamp":1792978267611,"version":"4.5.0"},"reference-count":34,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Purpose.\u2014To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers.<\/jats:p>\n                  <jats:p>Methods.\u2014The American Society of Clinical Oncology and the College of American Pathologists convened an international Expert Panel that conducted a systematic review and evaluation of the literature in partnership with Cancer Care Ontario and developed recommendations for optimal IHC ER\/PgR testing performance.<\/jats:p>\n                  <jats:p>Results.\u2014Up to 20% of current IHC determinations of ER and PgR testing worldwide may be inaccurate (false negative or false positive). Most of the issues with testing have occurred because of variation in preanalytic variables, thresholds for positivity, and interpretation criteria.<\/jats:p>\n                  <jats:p>Recommendations.\u2014The Panel recommends that ER and PgR status be determined on all invasive breast cancers and breast cancer recurrences. A testing algorithm that relies on accurate, reproducible assay performance is proposed. Elements to reliably reduce assay variation are specified. It is recommended that ER and PgR assays be considered positive if there are at least 1% positive tumor nuclei in the sample on testing in the presence of expected reactivity of internal (normal epithelial elements) and external controls. The absence of benefit from endocrine therapy for women with ER-negative invasive breast cancers has been confirmed in large overviews of randomized clinical trials.<\/jats:p>","DOI":"10.5858\/134.6.907","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T12:29:51Z","timestamp":1613132991000},"page":"907-922","source":"Crossref","is-referenced-by-count":452,"title":["American Society of Clinical Oncology\/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer"],"prefix":"10.5858","volume":"134","author":[{"given":"M. Elizabeth H.","family":"Hammond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Dowsett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Craig","family":"Allred","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Hagerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Badve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick L.","family":"Fitzgibbons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela B.","family":"Mangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Kent","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soonmyung","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Perlmutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Sasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared N.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred C. G.","family":"Sweep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Taube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emina Emilia","family":"Torlakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Valenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Visscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Bruce","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Wittliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio C.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2010,6,1]]},"reference":[{"key":"2021021103414072000_i1543-2165-134-6-907-b01","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021021103414072000_i1543-2165-134-6-907-b02","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"2021021103414072000_i1543-2165-134-6-907-b03","article-title":"Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays.","author":"Fitzgibbons","journal-title":"Arch Pathol Lab Med (in press)"},{"key":"2021021103414072000_i1543-2165-134-6-907-b04","first-page":"716","article-title":"Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.","volume":"109","author":"McCarty","year":"1985","journal-title":"Arch Pathol Lab Med"},{"key":"2021021103414072000_i1543-2165-134-6-907-b05","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/bjc.1996.563","article-title":"Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients.","volume":"74","author":"Barnes","year":"1996","journal-title":"Br J Cancer"},{"key":"2021021103414072000_i1543-2165-134-6-907-b06","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1200\/JCO.1999.17.5.1474","article-title":"Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.","volume":"17","author":"Harvey","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021021103414072000_i1543-2165-134-6-907-b07","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/(SICI)1097-0215(20000320)89:2<111::AID-IJC2>3.0.CO;2-W","article-title":"Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study.","volume":"89","author":"Elledge","year":"2000","journal-title":"Int J Cancer"},{"key":"2021021103414072000_i1543-2165-134-6-907-b08","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1054\/brst.2002.0451","article-title":"Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: Trial update and impact of immunohistochemical assessment of ER status.","volume":"11","author":"Thomson","year":"2002","journal-title":"Breast"},{"key":"2021021103414072000_i1543-2165-134-6-907-b09","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/jnci\/djj415","article-title":"Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays.","volume":"98","author":"Regan","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"2021021103414072000_i1543-2165-134-6-907-b10","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/modpathol.3800229","article-title":"Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study.","volume":"17","author":"Mohsin","year":"2004","journal-title":"Mod Pathol"},{"key":"2021021103414072000_i1543-2165-134-6-907-b11","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"2021021103414072000_i1543-2165-134-6-907-b12","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2007.13.6424","article-title":"Estrogen- and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.","volume":"26","author":"Badve","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021021103414072000_i1543-2165-134-6-907-b13","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1200\/JCO.2007.11.9453","article-title":"Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1\u201398.","volume":"25","author":"Viale","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021021103414072000_i1543-2165-134-6-907-b14","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.2007.10.6393","article-title":"Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors\u2014International Breast Cancer Study Group.","volume":"26","author":"Viale","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021021103414072000_i1543-2165-134-6-907-b15","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1200\/JCO.2005.05.4155","article-title":"Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.","volume":"24","author":"Cheang","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021021103414072000_i1543-2165-134-6-907-b16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/01.pai.0000213135.16783.bc","article-title":"Development of standard estrogen and progesterone receptor immunohistochemical assays for selection of patients for antihormonal therapy.","volume":"15","author":"Phillips","year":"2007","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2021021103414072000_i1543-2165-134-6-907-b17","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2007.12.9437","article-title":"Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial.","volume":"26","author":"Dowsett","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021021103414072000_i1543-2165-134-6-907-b18","first-page":"1","article-title":"Estrogen receptors in human breast cancer.","author":"McGuire","year":"1975","journal-title":"Estrogen Receptors in Human Breast Cancer"},{"key":"2021021103414072000_i1543-2165-134-6-907-b19","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U","article-title":"The value of estrogen and progesterone receptors in the treatment of breast cancer.","volume":"46","author":"Osborne","year":"1980","journal-title":"Cancer"},{"key":"2021021103414072000_i1543-2165-134-6-907-b20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0300-595X(80)80038-7","article-title":"Hormone receptors in primary and advanced breast cancer.","volume":"9","author":"Knight","year":"1980","journal-title":"Clin Endocrinol Metab"},{"key":"2021021103414072000_i1543-2165-134-6-907-b21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2559.1990.tb00735.x","article-title":"Oestrogen receptor in breast cancer: Prognostic studies using a new immunohistochemical assay.","volume":"17","author":"Cowen","year":"1990","journal-title":"Histopathology"},{"key":"2021021103414072000_i1543-2165-134-6-907-b22","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1158\/1078-0432.CCR-06-0248","article-title":"High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.","volume":"12","author":"Stendahl","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021021103414072000_i1543-2165-134-6-907-b23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/(SICI)1097-0215(19990621)84:3<203::AID-IJC1>3.0.CO;2-U","article-title":"A simple index using video image analysis to predict disease outcome in primary breast cancer.","volume":"84","author":"Lockwood","year":"1999","journal-title":"Int J Cancer"},{"key":"2021021103414072000_i1543-2165-134-6-907-b24","first-page":"138","article-title":"Quantitative immunohistochemical assay for hormonal receptors: Technical aspects and biological significance.","volume":"19","author":"Esteban","year":"1994","journal-title":"J Cell Biochem Suppl"},{"key":"2021021103414072000_i1543-2165-134-6-907-b25","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2325\/jbcs.13.74","article-title":"Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.","volume":"13","author":"Yamashita","year":"2006","journal-title":"Breast Cancer"},{"key":"2021021103414072000_i1543-2165-134-6-907-b26","first-page":"2535","article-title":"Immunohistochemical staining of estrogen and progesterone receptors: Aspects for evaluating positivity and defining the cutpoints.","volume":"25","author":"Jalava","year":"2005","journal-title":"Anticancer Res"},{"key":"2021021103414072000_i1543-2165-134-6-907-b27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF02984548","article-title":"Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: Analysis for a cut-off point as the predictor for endocrine therapy.","volume":"11","author":"Ogawa","year":"2004","journal-title":"Breast Cancer"},{"key":"2021021103414072000_i1543-2165-134-6-907-b28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1309\/9G5FY3U3QB4R15DR","article-title":"Unmasking the mysteries of antigen or epitope retrieval and formalin fixation.","volume":"121","author":"Gown","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"2021021103414072000_i1543-2165-134-6-907-b29","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0022-4731(76)90194-1","article-title":"Detection and dynamic localisation of estradiol-receptor complexes in intact target cells by immunofluorescence technique.","volume":"7","author":"Nenci","year":"1976","journal-title":"J Steroid Biochem"},{"key":"2021021103414072000_i1543-2165-134-6-907-b30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00125480-200501000-00003","article-title":"Estrogen receptor analysis for breast cancer: Current issues and keys to increasing testing accuracy.","volume":"12","author":"Diaz","year":"2005","journal-title":"Adv Anat Pathol"},{"key":"2021021103414072000_i1543-2165-134-6-907-b31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/PAI.0b013e31818a9d3a","article-title":"Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry.","volume":"16","author":"Yaziji","year":"2008","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2021021103414072000_i1543-2165-134-6-907-b32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1309\/QPHDRB00QXGMUQ9N","article-title":"Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma.","volume":"120","author":"Goldstein","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"2021021103414072000_i1543-2165-134-6-907-b33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2559.2006.02513.x","article-title":"Quantification of immunohistochemistry: Issues concerning methods, utility and semiquantitative assessment II.","volume":"49","author":"Taylor","year":"2006","journal-title":"Histopathology"},{"key":"2021021103414072000_i1543-2165-134-6-907-b34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/sonc.2002.33140","article-title":"Regulatory issues in tumor marker development.","volume":"29","author":"Gutman","year":"2002","journal-title":"Semin Oncol"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/134\/6\/907\/2769823\/1543-2165-134_6_907.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/134\/6\/907\/2769823\/1543-2165-134_6_907.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:35:59Z","timestamp":1764790559000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/134\/6\/article-p907.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,1]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,6,1]]},"published-print":{"date-parts":[[2010,6,1]]}},"URL":"https:\/\/doi.org\/10.5858\/134.6.907","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6,1]]}}}